AMEX · Biotechnology

CVM (CVM) Stock

$1.18 +0.00% AMEX: CVM Healthcare

Valuation

MetricValue
Price$1.18
Market Cap$8.11M
P/E Ratio-0.23
P/B Ratio0.62
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$13.48
52-Week Low$0.89
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-156.25%
ROA-89.29%
ROCE-156.25%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity1.24
Current Ratio2.40

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-36.0M$-36.0M$-31.0M$-26.0M$-25.0M
Net Profit$-39.0M$-38.0M$-32.0M$-27.0M$-25.0M
EPS$-28.80$-26.70$-21.90$-13.50$-6.27
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$76.0M$51.0M$31.0M$27.0M$28.0M
Total Liabilities$19.0M$18.0M$17.0M$14.0M$12.0M
Cash$36.0M$23.0M$4.0M$5.0M$11.0M
Borrowings$16.0M$15.0M$14.0M$12.0M$9.0M

Latest News

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer Business Wire · Jul 13, 2026 CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care Business Wire · Jun 24, 2026 CEL-SCI Closes $2.5 Million Stock Offering MT Newswires · Jun 16, 2026 CEL-SCI Announces Closing of Offering Business Wire · Jun 16, 2026 CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy Business Wire · Jun 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-18.0M$-23.0M$-19.0M$-17.1B
Investing Cash Flow$-24.0M$5.0M$-1.0M$0$-76.0M
Financing Cash Flow$6.0M$0$0$-2.0M$23.4B
Net Cash Flow$21.0M$-13.0M$-19.0M$1.0M$6.2B
Free Cash Flow$-28.0M$-19.0M$-23.0M$-19.0M$-17.2B

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-167.20%
Quick Ratio0.54
Interest Coverage-25.00
Return 1Y-67.42%
Return 3Y-98.50%
Return 5Y-99.52%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGS $4.28 -1.04% -2.29 $26.45M 0.00%
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
INMB $1.73 +6.79% -2.44 $45.99M 0.00%
KZR $7.29 +0.00% -0.96 $53.86M 0.00%

About CVM

CVM is led by CEO Geert R. Kersten, employs 43 people, headquartered in US, publicly traded since 1983.

CVM stock trades at $1.18 with a market capitalization of $8.11M. The stock is valued at a price-to-earnings (P/E) ratio of -0.23, price-to-book of 0.62, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.89 and $13.48, and currently trades 91.2% below its 52-week high.

On profitability, CVM generates a return on equity (ROE) of -156.25%, return on capital employed of -156.25%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides